GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

Phase 4

Completed

Conditions: Tetanus
Poliomyelitis
Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines
Acellular Pertussis
Diphtheria

Interventions: Biological: Infanrix hexa
Drug: Prevnar13

First Posted Date: 2015-04-21

Last Posted Date: 2019-07-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 601

Registration Number: NCT02422264

Locations: 🇪🇸
GSK Investigational Site, Sevilla, Spain

Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler

Phase 4

Completed

Conditions: Asthma

Interventions: Device: SERETIDE MDI
Device: Placebo DISKUS Inhaler
Device: Placebo MDI

First Posted Date: 2015-04-14

Last Posted Date: 2017-05-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 111

Registration Number: NCT02416180

Locations: 🇩🇪
GSK Investigational Site, Berlin, Germany

A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines

Completed

Conditions: Immunologic Tests

Interventions: Other: Serum samples

First Posted Date: 2015-04-14

Last Posted Date: 2019-07-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 414

Registration Number: NCT02415842

Locations: 🇺🇸
GSK Investigational Site, New York, New York, United States

Impact of Beverage Powder With Micronutrients and Brahmi Extract on Cognitive Variables in Indian School Children

Not Applicable

Completed

Conditions: Cognition

Interventions: Dietary Supplement: Beverage powder fortified with micronutrients and Bacopa monnieri extract
Other: Non fortified isocaloric control (without added micronutrients and Bacopa monnieri extract)

First Posted Date: 2015-04-14

Last Posted Date: 2015-07-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 310

Registration Number: NCT02416245

Locations: 🇮🇳
GSK Investigational Site, Pune, India

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

Conditions: Melanoma

First Posted Date: 2015-04-14

Last Posted Date: 2017-08-15

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT02416232

Locations: 🇫🇷
GSK Investigational Site, Villejuif cedex, France

A Tolerability Assessment Study of Three Wash Products in Infants

Not Applicable

Completed

Conditions: Skin Care

Interventions: Other: Test shampoo
Other: Test bath foam
Other: Test head to toe wash

First Posted Date: 2015-03-31

Last Posted Date: 2018-12-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 32

Registration Number: NCT02403999

Locations: 🇬🇧
GSK Investigational Site, Edinburgh, United Kingdom

Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol

Phase 4

Withdrawn

Conditions: Skin Irritation

Interventions: Other: Saline
Drug: Topical Spray
Drug: Topical Gel

First Posted Date: 2015-03-27

Last Posted Date: 2017-09-12

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT02400320

Evaluation of Oral Hygiene Products in an In Situ Caries Model

Not Applicable

Completed

Conditions: Dental Caries

Interventions: Drug: Fluoride free toothpaste
Drug: Fluoride toothpaste
Drug: Fluoride mouthwash

First Posted Date: 2015-03-26

Last Posted Date: 2016-05-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 80

Registration Number: NCT02399163

Locations: 🇺🇸
GSK Investigational Site, Indianapolis, Indiana, United States

Patient Preference Study of Fluticasone Furoate and Mometasone Furoate Nasal Sprays

Phase 4

Completed

Conditions: Rhinitis, Allergic, Perennial and Seasonal

Interventions: Drug: MF nasal spray
Drug: FF nasal spray

First Posted Date: 2015-03-25

Last Posted Date: 2018-01-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 300

Registration Number: NCT02397915

Locations: 🇷🇺
GSK Investigational Site, Stavropol, Russian Federation

A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of GSK2330811 in Healthy Subjects

Phase 1

Completed

Conditions: Scleroderma, Systemic

Interventions: Drug: GSK2330811
Drug: Placebo

First Posted Date: 2015-03-11

Last Posted Date: 2017-05-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 41

Registration Number: NCT02386436

Locations: 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy